BioMed X, an independent German biomedical research institute, said that it has extended its ongoing research collaboration with AbbVie (ABBV). This marks the launch of the first BioMed X Institute in the US, to be located in New Haven, Connecticut.
BioMed X noted that the new US-based research collaboration will focus on immunology and tissue engineering, following a first joint research project on Alzheimer's disease at the BioMed X Institute in Heidelberg, Germany.
The company stated that the new BioMed X Institute will be managed by Mark Johnston, an experienced biotech entrepreneur and business leader who recently joined BioMed X.
The current partnership with AbbVie is focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) from primary human cells and tissues to study human tissue inflammation.
For comments and feedback contact: editorial@rttnews.com
Business News